Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer Research|November 17, 2005
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cellsWassim Kassouf, Colin P N Dinney, Gordon Brown, et al.
Cancer Research|February 20, 2007
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expressionMarissa Shrader, Maria Simona Pino, Laura Lashinger, et al.
The Journal of Urology|April 18, 2007
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancerLiana Adam, Peter C Black, Wassim Kassouf, et al.
Molecular Cancer Therapeutics|January 24, 2007
Molecular correlates of gefitinib responsiveness in human bladder cancer cellsMarissa Shrader, Maria Simona Pino, Gordon Brown, et al.
Urologic Oncology|August 7, 2012
Plasma microRNA profiles for bladder cancer detectionLiana Adam, Matthew F Wszolek, Chang-Gong Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapyLiana Adam, Meng Zhong, Woonyoung Choi, et al.
Cancer Metastasis Reviews|December 17, 2009
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancerDavid J McConkey, Woonyoung Choi, Lauren Marquis, et al.
The Journal of Urology|December 21, 2010
Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancerPeter C Black, Gordon A Brown, Colin P Dinney, et al.
Nature|August 9, 2002
A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasmRakesh Kumar, Rui-An Wang, Abhijit Mazumdar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cellsZhibo Yang, Rozita Bagheri-Yarmand, Rui-An Wang, et al.
Pageof 3